Literature DB >> 24291546

Differential expression of SDF-1 isoforms in bladder cancer.

Miguel Gosalbez1, Marie C Hupe1,2, Soum D Lokeshwar3, Travis J Yates1, John Shields1, Muthu K Veerapen4, Axel S Merseburger2, Charles J Rosser5, Mark S Soloway1, Vinata B Lokeshwar1,3.   

Abstract

PURPOSE: SDF-1 is a ligand of the chemokine receptors CXCR4 and 7. The 6 known SDF-1 isoforms are generated by alternative mRNA splicing. While SDF-1 expression has been detected in various malignancies, only few groups have reported differential expression of SDF-1 isoforms and its clinical significance. We evaluated the expression of 3 SDF-1 isoforms (α, β and γ) in bladder cancer.
MATERIALS AND METHODS: Using quantitative polymerase chain reaction we measured SDF-1α, β and γ mRNA levels in 25 normal and 44 bladder cancer tissues, and in 210 urine specimens (28 normal, 74 benign, 57 bladder cancer, 35 bladder cancer history, 8 other cancer history and 8 other cancer) from consecutive patients. Levels were correlated with clinical outcome.
RESULTS: Of the SDF-1 isoforms only SDF-1β mRNA was significantly over expressed 2.5-fold to sixfold in bladder cancer compared to normal bladder tissues. SDF-1α was expressed in bladder tissues but SDF-1γ was undetectable. On multivariate analysis SDF-1β was an independent predictor of metastasis and disease specific mortality (p=0.017 and 0.043, respectively). In exfoliated urothelial cells only SDF-1β mRNA levels were differentially expressed with 91.2% sensitivity and 73.8% specificity for detecting bladder cancer. In patients with a bladder cancer history increased SDF-1β levels indicated a 4.3-fold increased risk of recurrence within 6 months (p=0.0001).
CONCLUSIONS: SDF-1 isoforms are differentially expressed in bladder tissues and exfoliated urothelial cells. SDF-1β mRNA levels in bladder cancer tissues predict a poor prognosis. Furthermore, SDF-1β mRNA levels in exfoliated cells detect bladder cancer with high sensitivity and they are a potential predictor of future recurrence.
Copyright © 2014 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  biological; chemokine CXCL12; local; neoplasm recurrence; prognosis; tumor markers; urinary bladder neoplasms

Mesh:

Substances:

Year:  2013        PMID: 24291546      PMCID: PMC4197846          DOI: 10.1016/j.juro.2013.11.053

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  29 in total

1.  Angiogenic effects of stromal cell-derived factor-1 (SDF-1/CXCL12) variants in vitro and the in vivo expressions of CXCL12 variants and CXCR4 in human critical leg ischemia.

Authors:  Teik K Ho; Janice Tsui; Shiwen Xu; Patricia Leoni; David J Abraham; Daryll M Baker
Journal:  J Vasc Surg       Date:  2010-03       Impact factor: 4.268

Review 2.  CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression.

Authors:  Xueqing Sun; Guangcun Cheng; Mingang Hao; Jianghua Zheng; Xiaoming Zhou; Jian Zhang; Russell S Taichman; Kenneth J Pienta; Jianhua Wang
Journal:  Cancer Metastasis Rev       Date:  2010-12       Impact factor: 9.264

3.  The expression of CXCR4, CXCL12 and CXCR7 in malignant pleural mesothelioma.

Authors:  Tong Li; Hui Li; Yucheng Wang; Chansonette Harvard; Jia-Li Tan; Alfred Au; Zhidong Xu; David M Jablons; Liang You
Journal:  J Pathol       Date:  2011-01-05       Impact factor: 7.996

4.  The potent anti-HIV activity of CXCL12gamma correlates with efficient CXCR4 binding and internalization.

Authors:  Jeffrey D Altenburg; Qingwen Jin; Bashar Alkhatib; Ghalib Alkhatib
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

Review 5.  The role of stromal-derived factor-1--CXCR7 axis in development and cancer.

Authors:  Radoslaw B Maksym; Maciej Tarnowski; Katarzyna Grymula; Joanna Tarnowska; Marcin Wysoczynski; Riu Liu; Boguslaw Czerny; Janina Ratajczak; Magda Kucia; Mariusz Z Ratajczak
Journal:  Eur J Pharmacol       Date:  2009-10-14       Impact factor: 4.432

Review 6.  The CXCR4/SDF-1 chemokine receptor axis: a new target therapeutic for non-small cell lung cancer.

Authors:  Shannon Otsuka; Gwyn Bebb
Journal:  J Thorac Oncol       Date:  2008-12       Impact factor: 15.609

Review 7.  The role of CXC chemokines and their receptors in cancer.

Authors:  Jo Vandercappellen; Jo Van Damme; Sofie Struyf
Journal:  Cancer Lett       Date:  2008-06-24       Impact factor: 8.679

8.  SDF-1alpha promotes invasion of head and neck squamous cell carcinoma by activating NF-kappaB.

Authors:  Aasia O Rehman; Cun-Yu Wang
Journal:  J Biol Chem       Date:  2008-04-30       Impact factor: 5.157

9.  CXCR4 expression reflects tumor progression and regulates motility of bladder cancer cells.

Authors:  Margitta M Retz; Sukhvinder S Sidhu; Ekaterina Blaveri; Sheena C Kerr; Gregory M Dolganov; Jan Lehmann; Peter Carroll; Jeff Simko; Frederic M Waldman; Carol Basbaum
Journal:  Int J Cancer       Date:  2005-03-20       Impact factor: 7.396

10.  A chemokine targets the nucleus: Cxcl12-gamma isoform localizes to the nucleolus in adult mouse heart.

Authors:  Raul Torres; Juan C Ramirez
Journal:  PLoS One       Date:  2009-10-27       Impact factor: 3.240

View more
  3 in total

Review 1.  Biological/pathological functions of the CXCL12/CXCR4/CXCR7 axes in the pathogenesis of bladder cancer.

Authors:  Alireza Nazari; Hossein Khorramdelazad; Gholamhossein Hassanshahi
Journal:  Int J Clin Oncol       Date:  2017-10-11       Impact factor: 3.402

2.  Mincle, an Innate Immune Receptor, Is Expressed in Urothelial Cancer Cells of Papillomavirus-Associated Urothelial Tumors of Cattle.

Authors:  Sante Roperto; Valeria Russo; Iolanda Esposito; Dora Maria Ceccarelli; Orlando Paciello; Luigi Avallone; Rosanna Capparelli; Franco Roperto
Journal:  PLoS One       Date:  2015-10-29       Impact factor: 3.240

3.  A Comprehensive Analysis of CXCL12 Isoforms in Breast Cancer1,2.

Authors:  Shuang Zhao; S Laura Chang; Jennifer J Linderman; Felix Y Feng; Gary D Luker
Journal:  Transl Oncol       Date:  2014-05-13       Impact factor: 4.243

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.